Eli Lilly Trial - Search News

Novo Nordisk, obesity and Eli Lilly

Reuters on MSN · 3d

Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over Novo in the weight-loss drugs market.

Barron's on MSN · 3d

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Investopedia on MSN · 1d

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce treatments using Zealand's experimental petrelintide injectable.

3d

Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

10h

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

2don MSN

Is Eli Lilly Stock a Buy?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

3d

Eli Lilly’s three-year Ebglyss study leaves 50% of AD patients with clear skin

The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...

BioPharma Dive3d

Novo’s Wegovy successor disappoints in second large trial

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results